Search
Munich based Ethris is developing a proprietary mRNA and lipid nanoparticle combination that is stable and allows for nasal administration or to be inhaled via nebulization
- blonca9
- 1 day ago
- 1 min read
CEO Carsten Rudolph and CMO Thomas Langenickel describe the technology, which can be spray dried and shipped in a dry powder formulation, and also the clinical experience so far on the lead program in asthma.